SCHEMBL667453

SCHEMBL667453

CC(C)Oc1ccccc1C(C(N)=O)c1nccs1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CTSA P10619 5/20 0.48
IRAK4 Q9NWZ3 2/20 0.43
F7 P08709 1/20 0.40
ALDH1A1 P00352 1/20 0.39
ACHE P22303 1/20 0.39
ALOX15 P16050 1/20 0.37
MAPK1 P28482 1/20 0.37
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36
RBBP9 O75884 1/20 0.36
SLC9A1 P19634 1/20 0.36
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
ADRB2 P07550 1/20 0.35
MAP2 P11137 1/20 0.35
HIF1A Q16665 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL666602 0.88 CTSA (0.52) CTSAMEN1KMT2ANPC1RAB9A
SCHEMBL664542 0.86 ALOX15 (0.48) CTSAF7ALDH1A1ALOX15MAPK1
SCHEMBL662588 0.83 CTSA (0.40) CTSAALDH1A1RBBP9NPC1RAB9A
SCHEMBL662300 0.78 CYP1A2 (0.41) CTSAKMT2A
SCHEMBL667099 0.75 CTSA (0.46) CTSAALDH1A1KMT2ANPC1RAB9A
SCHEMBL666275 0.75 HDAC3 (0.38) CTSAALDH1A1NPC1RAB9A
SCHEMBL7330787 0.72 IRAK4 (0.59) IRAK4ALDH1A1ACHESLC9A1KMT2A
SCHEMBL3263348 0.70 TRPA1 (0.36) CTSANPC1
SCHEMBL4562114 0.69 PORCN (0.44) CTSAALDH1A1MEN1KMT2A
SCHEMBL665545 0.69 ALOX5 (0.47) CTSAALDH1A1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180133170-A1 METHODS AND COMPOSITIONS FOR TREATING DISORDERS ELI LILLY AND COMPANY 2018-05-17 US disclosed
US-20130165427-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES HYDRA BIOSCIENCES, INC. (US) 2013-06-27 US disclosed
US-20130059869-A1 METHODS AND COMPOSITIONS FOR TREATING DISORDERS HYDRA BIOSCIENCES, INC. 2013-03-07 US disclosed
US-20120108614-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES HYDRA BIOSCIENCES, INC. 2012-05-03 US disclosed
US-8163761-B2 Methods and compositions for treating disorders HYDRA BIOSCIENCES, INC. (US) 2012-04-24 US disclosed
US-20120046305-A1 METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY DISORDERS ELI LILLY AND COMPANY 2012-02-23 US disclosed
US-20090143377-A1 METHODS AND COMPOSITIONS FOR TREATING DISORDERS ELI LILLY AND COMPANY 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108614-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES ELANE, CASP3, MMP8 CTSA 221/4885IRAK4 2934/4885F7 729/4885
US-20180133170-A1 METHODS AND COMPOSITIONS FOR TREATING DISORDERS TRPA1, TRPV1, TRPV3 CTSA 1159/4885IRAK4 3023/4885F7 4732/4885
US-20090143377-A1 METHODS AND COMPOSITIONS FOR TREATING DISORDERS TRPA1, TRPV1, TRPV3 CTSA 1159/4885IRAK4 3023/4885F7 4732/4885
US-20120046305-A1 METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY DISORDERS TRPA1, TRPV1, TRPV3 CTSA 1437/4885IRAK4 2248/4885F7 4544/4885
US-20130165427-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES ELANE, CASP3, MMP8 CTSA 221/4885IRAK4 2934/4885F7 729/4885
US-20130059869-A1 METHODS AND COMPOSITIONS FOR TREATING DISORDERS TRPA1, TRPV1, TRPV3 CTSA 1159/4885IRAK4 3023/4885F7 4732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.